B
Beren Therapeutics
Cyclodextrin-based therapeutics for defective cholesterol trafficking conditions
About Beren Therapeutics
Beren Therapeutics, P.B.C. is a clinical-stage biotechnology company founded in 2020 and co-founded by CEO Jason Camm, who also serves as the Chief Medical Officer of Thiel Capital. Operating as a Public Benefit Corporation, the firm is headquartered in Thousand Oaks, California, with a subsidiary in Japan, Beren Therapeutics K.K., established in 2025. The company focuses on developing and commercializing cyclodextrin-based therapeutics to address a range of intractable diseases characterized by defective cholesterol trafficking.
The core of Beren's technology utilizes the unique ring-shaped structure of cyclodextrins, a type of oligosaccharide, to selectively encapsulate pathogenic compounds. The initial focus is on conditions involving the abnormal accumulation of cholesterol within cells, which is a pathogenic factor in numerous diseases. The company operates in stealth mode alongside its public-facing subsidiary, Mandos LLC, which it uses to advance specific drug programs. In 2021, Beren, through Mandos, acquired the adrabetadex program from Mallinckrodt. This investigational drug recently received Breakthrough Therapy Designation from the U.S. FDA for treating infantile-onset Niemann-Pick disease type C (NPC), a rare genetic disorder.
Beren Therapeutics has secured a total of $130 million in funding across several rounds. Its investors include UTokyo Innovation Platform Company, JIC Venture Growth Investments, Roquette, Alpha Wave Global, and Thiel Capital, among others. The company has established strategic partnerships, including an innovation agreement with Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, to explore the full potential of its cyclodextrin technologies. This collaboration aims to enhance chemistry, manufacturing, and controls (CMC) management and accelerate development. Beren Therapeutics is also actively working to expand its discovery operations into Japan, collaborating with local talent and researchers to grow its pipeline and address unmet medical needs globally.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Jun 2026 | $165M | — | Hercules Capital | ↗ |
| LATE VCOther financing | Jun 2026 | $135M | $540M | Wellington Partners · Eisai · JIC Venture Growth Investments · Founders Fund | ↗ |
Growth signals
Latest recorded traffic for Beren Therapeutics is 5.4K monthly website visits, up 157.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
R1 TherapeuticsPharmaceutical therapies targeting neurological, metabolic and infectious conditions |
Temecula, United States | Operational | 16 | $78M | $310M |
| — | Operational | ||||
CardiomedexPreclinical CRO for cardiovascular drug candidate development |
Escalquens, France | Operational | |||
| Seattle, United States | Operational | ||||
Braveheart BioLate-stage therapeutics for hypertrophic cardiomyopathy |
San Francisco, United States | Operational | |||
| — | Operational | ||||
Agiana PharmaceuticalsNovel anti-arrhythmic therapy for cardiac rhythm management |
Oslo, Norway | Operational | |||
Hygen Health Private LimitedPharmaceuticals for cardiovascular, diabetes, and neurological disorders |
— | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beren Therapeutics in the Thousand Oaks ecosystem
The Beren Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Roquette
Series B and later6 investors entered at this stage
Hercules Capital
Wellington Partners
Eisai
JIC Venture Growth Investments
Founders Fund
Narya Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beren Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beren Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






